Can COVID-19 cause atypical forms of pityriasis rosea refractory to conventional therapies?

Martora, Fabrizio; Picone, Vincenzo; Fornaro, Luigi; Fabbrocini, Gabriella; Marasca, Claudio

Martora, Fabrizio; Picone, Vincenzo; Fornaro, Luigi; Fabbrocini, Gabriella; Marasca, Claudio.

Martora F; Department of Clinical Medicine and Surgery, Section of Dermatology, University Hospital Federico II of Naples, Italy.
Picone V; Department of Clinical Medicine and Surgery, Section of Dermatology, University Hospital Federico II of Naples, Italy.
Fornaro L; Department of Clinical Medicine and Surgery, Section of Dermatology, University Hospital Federico II of Naples, Italy.
Fabbrocini G; Department of Clinical Medicine and Surgery, Section of Dermatology, University Hospital Federico II of Naples, Italy.
Marasca C; Department of Clinical Medicine and Surgery, Section of Dermatology, University Hospital Federico II of Naples, Italy.

J Med Virol ; 94(4): 1292-1293, 2022 04.

Article in English | MEDLINE | ID: covidwho-1589035

Subject(s)

COVID-19; Pityriasis Rosea; Humans; Pityriasis Rosea/diagnosis; Pityriasis Rosea/drug therapy; SARS-CoV-2; Skin

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pityriasis Rosea / COVID-19 Type of study: Diagnostic study Limits: Humans Language: English Journal: J Med Virol Year: 2022 Document Type: Article Affiliation country: Jmv.27535

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google